As per Red - trial put on hold pending outcome of pediatric BLA.
Risk management of worst case scenario
Third CRL issued
Only way to prove up Remestemcel-l is to conduct an RCT in adults.
Why delay the trial when it's 5 times the paediatric market and funded.
Delay is non sensical unless they plan to scrap the entire aGvHD program- result - share price devastation - impossible to raise funds .
Or they have delayed because an approval in kids will lead to a label expansion in adults - same disease - potency varies by weight only. Real world evidence from the EAP and CIBMTR long term survival data.
Im not pumping- trying to get in the mind of the board.
Why the delay - Why the debt retirement
Im all ears for counter arguments
Reg
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-109
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.005(0.45%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.15 | $1.11 | $5.667M | 5.064M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 94111 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 70945 | 3 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
-0.005 ( 1.73 %) |
||||
| Open | High | Low | Volume | ||
| $1.11 | $1.15 | $1.11 | 871975 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| MSB (ASX) Chart |